Real-life experience of using pegylated liposomal doxorubicin in primary cutaneous T-cell lymphomas.
Clin Exp Dermatol
; 47(9): 1712-1715, 2022 Sep.
Article
em En
| MEDLINE
| ID: mdl-35426448
ABSTRACT
Mycosis fungoides (MF) is the most prevalent subtype of primary cutaneous T-cell lymphomas (CTCLs). Sézary syndrome (SS) is another entity defined by leukaemic involvement, lymphadenopathy and erythroderma. Pegylated liposomal doxorubicin (PEG-DOXO) is an anthracycline used in the management of advanced primary CTCL, particularly in induction strategies. However, there are limited data on its effectiveness and tolerability in real-life patients. We report 36 patients who received PEG-DOXO for MF or SS in our centre, describing the patients' characteristics, response rates and tolerance to the treatment. The best overall responses were observed for the skin, with lower response rates for nodal involvement and moderate responses for blood disease. The treatment was mainly well tolerated, without severe adverse events, and no cardiotoxicity was observed on cardiac function monitoring.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Cutâneas
/
Linfoma Cutâneo de Células T
/
Micose Fungoide
/
Síndrome de Sézary
Limite:
Humans
Idioma:
En
Revista:
Clin Exp Dermatol
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Espanha